IL-27/IL-35 EBI3 Subunit (Dimer), (Heterodimer), (Monomer) 抗体
适用: 小鼠
FACS
宿主: 大鼠
Monoclonal
J053B5
unconjugated
1 image
-
- 抗原
- IL-27/IL-35 EBI3 Subunit
- 抗原表位
- Dimer, Heterodimer, Monomer
- 适用
- 小鼠
- 宿主
- 大鼠
- 克隆类型
- 单克隆
- 应用范围
- Flow Cytometry (FACS)
- 纯化方法
- The antibody was purified by affinity chromatography.
- 克隆位点
- J053B5
- 亚型
- IgG2a
-
- 应用备注
- Optimal working dilution should be determined by the investigator.
- 限制
- 仅限研究用
-
- 浓度
- 0.5 mg/mL
- 缓冲液
- Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.
- 储存液
- Sodium azide
- 注意事项
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- 储存条件
- 4 °C
- 储存方法
- The antibody solution should be stored undiluted between 2°C and 8°C.
-
- 抗原
- IL-27/IL-35 EBI3 Subunit
- 别名
- IL-27/IL-35 EBI3
- 背景
- EBI3 is an IL-12 p40-related protein that can heterodimerized with IL-12 p35 to form IL-35, or with an IL-12 p35-related protein, p28, to form IL-27. It is produced by antigen-presenting cells such as B cells, monocytes, and dendritic cells (DCs) following stimulation through TLR. It can regulate T cell differentiation and proliferation. Both IL-27 and IL-35 are anti-inflammatory cytokines that are able to inhibit Th17 generation, promote Th1 differentiation, increase cytolytic activity of CD8+ T cells, and impact B cell differentiation and immunoglobulin production. IL-35 is also involved in tumorigenesis and is a promising biomarker for assessing tumor progression and prognosis in clinical settings.
-
You are here:
